Ovid Therapeutics Inc. - 10-Q Filing

Ovid Therapeutics reports Q3 2026 financial results including details on Series A and B convertible preferred stock and warrant valuations.

SEC EDGAR ·

Tickers: $OVID

Read the full article at SEC EDGAR

More Regulatory news